SCHEMBL5652382

SCHEMBL5652382

CCOC(=O)c1sc2c(ccc(=O)n2-c2cccc(Br)c2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 1/20 0.43
MAPT P10636 6/20 0.43
ALDH1A1 P00352 5/20 0.43
HSD17B10 Q99714 3/20 0.43
MEN1 O00255 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX15 P16050 2/20 0.41
ALOX5 P09917 2/20 0.40
PTGES O14684 1/20 0.40
MAT2A P31153 1/20 0.40
CYP19A1 P11511 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651739 0.90 ALDH1A1 (0.44) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5650136 0.90 MAPT (0.51) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5653063 0.89 ALDH1A1 (0.52) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5652339 0.89 MAPT (0.44) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5648182 0.89 TRPM8 (0.45) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5650917 0.86 MAPT (0.46) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5651579 0.86 FNTA (0.49) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5653998 0.85 MAPT (0.48) MAPTALDH1A1MEN1NPC1RAB9A
SCHEMBL5650867 0.85 MAPT (0.47) MAPTALDH1A1HSD17B10MEN1NPC1
SCHEMBL5651738 0.85 TRPM8 (0.48) MAPTALDH1A1HSD17B10MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 DCTPP1 2935/4885MAPT 3795/4885ALDH1A1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.